A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.

November 9, 2018

Type of Cancer

Skin and Soft Tissue

Site

Hackensack

Sponsor

Bristol-Myers Squibb

Protocol Number

Bristol-Myers Squibb CA045-001

To Learn More Call

(201)-510-0950